Amanote Research
Register
Sign In
Low Dose Liposomal Amphotericin B Seems to Be Effective Against Visceral Leishmaniasis
BMJ
doi 10.1136/bmj.323.7310.0b
Full Text
Open PDF
Abstract
Available in
full text
Date
August 25, 2001
Authors
Unknown
Publisher
BMJ
Related search
Liposomal Amphotericin B
Medical mycology journal
Infectious Diseases
Microbiology
Treatment of Experimental Visceral Leishmaniasis With Amphotericin B in Stable Albumin Microspheres
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Therapeutic and Immunomodulatory Activities of Short-Course Treatment of Murine Visceral Leishmaniasis With KALSOME™10, a New Liposomal Amphotericin B
BMC Infectious Diseases
Infectious Diseases
Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients Following Treatment With 20 Mg/Kg Liposomal Amphotericin B (Ambisome) in Bihar, India
PLoS Neglected Tropical Diseases
Pharmacology
Public Health
Environmental
Toxicology
Infectious Diseases
Pharmaceutics
Occupational Health
American Cutaneous Leishmaniasis in French Guiana: A Retrospective Comparison Between Liposomal Amphotericin B and Meglumine Antimoniate
British Journal of Dermatology
Dermatology
Medicine
Safety and Effectiveness of Amphotericin B Deoxycholate for the Treatment of Visceral Leishmaniasis in Uganda
Annals of Tropical Medicine & Parasitology
RecurrentCandida albicansVentriculitis Treated With Intraventricular Liposomal Amphotericin B
Case Reports in Infectious Diseases
Dose Range Evaluation of Liposomal Nystatin and Comparisons With Amphotericin B and Amphotericin B Lipid Complex in Temporarily Neutropenic Mice Infected With an Isolate of Aspergillus Fumigatus With Reduced Susceptibility to Amphotericin B
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Liposomal Amphotericin B Inhibits in Vitro T-Lymphocyte Response to Antigen.
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
